Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

NCT04845399 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Sponsor

Zhengzhou Gensciences Inc

Collaborators

[object Object]